Total Payments
$38,217
2023 Payments
$10,192
Companies
12
Transactions
36
Medicare Patients
1,416
Medicare Billing
$109,235
Payment Breakdown by Category
Consulting$35,380 (92.6%)
Travel$1,499 (3.9%)
Food & Beverage$765.31 (2.0%)
Research$525.00 (1.4%)
Education$47.46 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $35,380 | 18 | 92.6% |
| Travel and Lodging | $1,499 | 6 | 3.9% |
| Food and Beverage | $765.31 | 9 | 2.0% |
| Unspecified | $525.00 | 1 | 1.4% |
| Education | $47.46 | 2 | 0.1% |
Payments by Type
General
$37,692
35 transactions
Research
$525.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $8,387 | 12 | $0 (2023) |
| Galderma Laboratories, L.P. | $8,139 | 5 | $0 (2021) |
| Janssen Research & Development, LLC | $7,440 | 4 | $0 (2022) |
| ARGENX US, INC. | $5,625 | 2 | $0 (2023) |
| Genentech USA, Inc. | $4,121 | 4 | $0 (2017) |
| Grifols, S.A. | $2,000 | 3 | $0 (2022) |
| BIOVERATIV THERAPEUTICS INC. | $1,800 | 1 | $0 (2018) |
| Eli Lilly and Company | $525.00 | 1 | $0 (2017) |
| AbbVie, Inc. | $103.94 | 1 | $0 (2017) |
| PFIZER INC. | $34.95 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $10,192 | 11 | AstraZeneca UK Limited ($6,442) |
| 2022 | $6,628 | 6 | Janssen Research & Development, LLC ($4,340) |
| 2021 | $6,200 | 4 | Janssen Research & Development, LLC ($3,100) |
| 2020 | $2,445 | 3 | AstraZeneca UK Limited ($1,945) |
| 2019 | $3,139 | 2 | Galderma Laboratories, L.P. ($3,139) |
| 2018 | $4,835 | 3 | Galderma Laboratories, L.P. ($3,000) |
| 2017 | $4,779 | 7 | Genentech USA, Inc. ($4,121) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/28/2023 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Immunology | ||||||
| 05/30/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $5,370.00 | General |
| Category: Respiratory | ||||||
| 02/27/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $369.90 | General |
| Category: Respiratory | ||||||
| 02/27/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $140.07 | General |
| Category: Respiratory | ||||||
| 02/27/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Food and Beverage | In-kind items and services | $78.07 | General |
| Category: Respiratory | ||||||
| 02/27/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Food and Beverage | In-kind items and services | $63.00 | General |
| Category: Respiratory | ||||||
| 02/27/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $60.89 | General |
| Category: Respiratory | ||||||
| 02/27/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Food and Beverage | In-kind items and services | $41.09 | General |
| Category: Respiratory | ||||||
| 02/27/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: Respiratory | ||||||
| 02/27/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Respiratory | ||||||
| 02/26/2023 | AstraZeneca UK Limited | FASENRA (Biological) | Travel and Lodging | In-kind items and services | $267.10 | General |
| Category: Respiratory | ||||||
| 08/02/2022 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| 07/01/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| 05/09/2022 | Incyte Corporation | OPZELURA (Drug) | Education | Cash or cash equivalent | $12.51 | General |
| Category: Dermatology | ||||||
| 03/15/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $620.00 | General |
| 01/17/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,240.00 | General |
| 01/10/2022 | Grifols, S.A. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 09/21/2021 | Grifols, S.A. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 05/14/2021 | Grifols, S.A. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 03/29/2021 | Galderma Laboratories, L.P. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 03/24/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| 11/20/2020 | AstraZeneca UK Limited | FASENRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,556.00 | General |
| Category: Respiratory | ||||||
| 08/27/2020 | AstraZeneca UK Limited | FASENRA (Drug) | Consulting Fee | Cash or cash equivalent | $389.00 | General |
| Category: Respiratory | ||||||
| 03/13/2020 | Galderma Laboratories, L.P. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 04/17/2019 | Galderma Laboratories, L.P. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 329 | 470 | $150,656 | $30,113 |
| 2022 | 6 | 337 | 505 | $126,518 | $26,847 |
| 2021 | 10 | 398 | 542 | $141,453 | $31,286 |
| 2020 | 7 | 352 | 511 | $106,416 | $20,987 |
Total Patients
1,416
Total Services
2,028
Medicare Billing
$109,235
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 109 | 162 | $72,422 | $15,369 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 97 | 112 | $34,910 | $6,529 | 18.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $12,156 | $2,806 | 23.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 40 | 45 | $11,133 | $1,847 | 16.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 18 | 19 | $7,209 | $1,279 | 17.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $5,134 | $953.76 | 18.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 13 | 13 | $5,468 | $916.20 | 16.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 23 | 90 | $2,224 | $413.85 | 18.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 83 | 128 | $53,600 | $11,675 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 108 | 114 | $33,860 | $7,401 | 21.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 28 | 35 | $13,780 | $2,812 | 20.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 50 | 53 | $12,181 | $2,259 | 18.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 26 | 27 | $9,725 | $1,951 | 20.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 42 | 148 | $3,372 | $750.27 | 22.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 100 | 141 | $53,465 | $13,835 | 25.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 88 | 94 | $24,968 | $4,998 | 20.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 58 | 60 | $13,843 | $2,196 | 15.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $8,720 | $1,920 | 22.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $7,716 | $1,857 | 24.1% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 25 | 25 | $8,898 | $1,838 | 20.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 24 | 24 | $8,682 | $1,762 | 20.3% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 23 | 24 | $9,474 | $1,715 | 18.1% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 11 | 11 | $2,794 | $593.00 | 21.2% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 42 | 136 | $2,893 | $572.51 | 19.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 146 | 185 | $45,096 | $8,979 | 19.9% |
About Ron Feldman, MD, PHD
Ron Feldman, MD, PHD is a Dermatology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/14/2008. The National Provider Identifier (NPI) number assigned to this provider is 1316123821.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ron Feldman, MD, PHD has received a total of $38,217 in payments from pharmaceutical and medical device companies, with $10,192 received in 2023. These payments were reported across 36 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($35,380).
As a Medicare-enrolled provider, Feldman has provided services to 1,416 Medicare beneficiaries, totaling 2,028 services with total Medicare billing of $109,235. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Atlanta, GA
- Active Since 01/14/2008
- Last Updated 11/19/2018
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1316123821
Products in Payments
- FASENRA (Biological) $6,442
- Rituxan (Biological) $4,121
- VYVGART (Drug) $3,750
- FASENRA (Drug) $1,945
- NO PRODUCT DISCUSSED (Drug) $1,800
- Humira (Biological) $103.94
- EUCRISA (Drug) $34.95
- TALTZ (Drug) $28.89
- OPZELURA (Drug) $12.51
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Atlanta
Dr. Zakiya Rice, Md, MD
Dermatology — Payments: $920,568
Dermatology $920,568
Dr. Mack Rachal, M.d, M.D
Dermatology — Payments: $478,485
Dermatology $478,485
Dr. Anna Pare', M.d, M.D
Dermatology — Payments: $54,847
Dermatology $54,847
Sarah Chisolm, M.d, M.D
Dermatology — Payments: $44,095
Dermatology $44,095
Lauren Orenstein, Md, MD
Dermatology — Payments: $27,645
Dermatology $27,645
Dr. Suephy Chen, Md, MD
Dermatology — Payments: $19,150
Dermatology $19,150